(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
These men carry towers of birds through Mexico's streets. They say their tradition is dying out. - 2The architect of Iran’s military survival remains defiant
- 3San Francisco sues 10 companies that make ultraprocessed food
- 4The Developing Nearby Food Development and Its Advantages
- 5Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
- Grasping the Commencement of Criminal Cases: An Extensive Outline
- Netanyahu expects Iran's leadership to fall
- Pfizer in $41.5 million settlement with Texas over ADHD drug for children
- Sean Penn lights up, Kylie Jenner gets A-list approval and 7 other moments you didn’t see at the Golden Globes
- Explainer-Why are hepatitis B vaccines given to newborns?
- How food assistance programs can feed families and nourish their dignity
- Find the Lively Food Markets of South America
- Trump says Venezuela will start 'turning over' oil to the U.S. Is that the reason he toppled Maduro — or is it something else?
- 10 Delectable Specialty Mixed drinks
